Kiniksa Pharmaceuticals (KNSA) Short Interest Ratio & Short Volume → DON’T buy gold until you read this (From Sasco Gold LLC) (Ad) Free KNSA Stock Alerts $19.22 +0.16 (+0.84%) (As of 06/10/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Kiniksa Pharmaceuticals Short Interest DataCurrent Short Interest3,990,000 sharesPrevious Short Interest3,910,000 sharesChange Vs. Previous Month+2.05%Dollar Volume Sold Short$80.20 millionShort Interest Ratio10.5 Days to CoverLast Record DateMay 15, 2024Outstanding Shares70,940,000 sharesPercentage of Shares Shorted5.62%Today's Trading Volume229,117 sharesAverage Trading Volume380,748 sharesToday's Volume Vs. Average60% Short Selling Kiniksa Pharmaceuticals ? Sign up to receive the latest short interest report for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKNSA Short Interest Over TimeKNSA Days to Cover Over TimeKNSA Percentage of Float Shorted Over Time Ad Sasco Gold LLCDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is for YOU. 99% of people are buying gold the wrong way.Reserve your seat here. Kiniksa Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20243,990,000 shares $80.20 million +2.1%N/A10.5 $20.10 4/30/20243,910,000 shares $73.20 million +7.4%N/A10.1 $18.72 4/15/20243,640,000 shares $63.48 million +13.4%N/A9.9 $17.44 3/31/20243,210,000 shares $63.33 million +11.9%N/A8.5 $19.73 3/15/20242,870,000 shares $57.37 million +3.2%N/A6.9 $19.99 2/29/20242,780,000 shares $58.77 million +3.0%N/A6.2 $21.14 Get the Latest News and Ratings for KNSA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/20242,700,000 shares $54.46 million -2.2%N/A6.3 $20.17 1/31/20242,760,000 shares $48.66 million +5.8%N/A6.2 $17.63 1/15/20242,610,000 shares $49.25 million -9.1%N/A5.4 $18.87 12/31/20232,870,000 shares $50.34 million -12.5%N/A6.1 $17.54 12/15/20233,280,000 shares $59.01 million -4.4%N/A8 $17.99 11/30/20233,430,000 shares $55.46 million +0.6%N/A9.5 $16.17 11/15/20233,410,000 shares $53.64 million +6.2%N/A10.3 $15.73 10/31/20233,210,000 shares $48.95 million -17.7%N/A9.5 $15.25 10/15/20233,900,000 shares $63.61 million +0.8%N/A8.8 $16.31 9/30/20233,870,000 shares $67.22 million +1.3%N/A8.2 $17.37 9/15/20233,820,000 shares $65.47 million -0.8%N/A8 $17.14 8/31/20233,850,000 shares $66.34 million -1.5%N/A7.5 $17.23 8/15/20233,910,000 shares $64.91 million +13.7%N/A7.3 $16.60 7/31/20233,440,000 shares $64.81 million +30.8%N/A6.4 $18.84 7/15/20232,630,000 shares $38.21 million -1.1%N/A5.3 $14.53 6/30/20232,660,000 shares $37.45 million -2.9%N/A6.6 $14.08 6/15/20232,740,000 shares $44.83 million +3.4%N/A6.7 $16.36 5/31/20232,650,000 shares $36.73 million -4.7%N/A6.3 $13.86 5/15/20232,780,000 shares $39.89 million -11.5%N/A6.5 $14.35 4/30/20233,140,000 shares $33.76 million +8.3%N/A7.5 $10.75 4/15/20232,900,000 shares $32.92 million -3.7%N/A7.6 $11.35 3/31/20233,010,000 shares $32.39 million +19.4%N/A7.7 $10.76 3/15/20232,520,000 shares $28.78 million -7.4%N/A6.7 $11.42 2/28/20232,720,000 shares $34.98 million -0.4%N/A7.6 $12.86 2/15/20232,730,000 shares $36.80 million -0.7%N/A7.9 $13.48 1/31/20232,750,000 shares $39.77 million -4.8%N/A7.5 $14.46 1/15/20232,890,000 shares $42.05 million +2.5%N/A7.7 $14.55 12/30/20222,820,000 shares $42.24 million +38.2%N/A7.3 $14.98 12/15/20222,040,000 shares $32.19 million -22.7%N/A5.3 $15.78 11/30/20222,640,000 shares $44.43 million -5.4%N/A7.5 $16.83 11/15/20222,790,000 shares $43.97 million +2.2%N/A8.1 $15.76 10/31/20222,730,000 shares $31.18 million +3.0%N/A8.2 $11.42 10/15/20222,650,000 shares $35.96 million -8.0%N/A7.8 $13.57 9/30/20222,880,000 shares $36.98 million +18.5%N/A8.2 $12.84DON’T buy gold until you read this (Ad)If you're an American who understands that your money is rotting away as you read this email… Then this is for YOU. 99% of people are buying gold the wrong way.Reserve your seat here. 9/15/20222,430,000 shares $25.44 million +7.5%N/A7.8 $10.47 8/31/20222,260,000 shares $26.49 million +15.3%N/A6.9 $11.72 8/15/20221,960,000 shares $24.42 million +1.6%N/A5.9 $12.46 7/31/20221,930,000 shares $19.13 million -18.2%N/A5.7 $9.91 7/15/20222,360,000 shares $26.55 million -2.9%N/A8.3 $11.25 6/30/20222,430,000 shares $23.55 million -4.7%N/A8.9 $9.69 6/15/20222,550,000 shares $21.78 million +2.4%N/A9.2 $8.54 5/31/20222,490,000 shares $19.07 million +1.6%N/A8.1 $7.66 5/15/20222,450,000 shares $20.14 million +7.0%N/A7.7 $8.22 4/30/20222,290,000 shares $21.37 million -0.9%N/A7.3 $9.33 4/15/20222,310,000 shares $25.94 million -10.5%N/A7 $11.23 3/31/20222,580,000 shares $25.65 million -20.9%N/A7.3 $9.94 3/15/20223,260,000 shares $30.97 million -0.6%N/A8.4 $9.50 2/28/20223,280,000 shares $33.59 million +16.7%N/A8.1 $10.24 2/15/20222,810,000 shares $31.95 million +3.3%N/A6.9 $11.37 1/31/20222,720,000 shares $30.55 million +19.3%8.5%6.8 $11.23 1/15/20222,280,000 shares $25.83 million +0.9%N/A5.3 $11.33 12/31/20212,260,000 shares $26.60 million -15.7%N/A5.6 $11.77 12/15/20212,680,000 shares $35.32 million +10.3%N/A7 $13.18 11/30/20212,430,000 shares $28.24 million +12.0%N/A7.2 $11.62 11/15/20212,170,000 shares $28.28 million -33.0%N/A6.5 $13.03 10/29/20213,240,000 shares $33.66 million +1.6%N/A9.1 $10.39 10/15/20213,190,000 shares $36.53 million -11.6%10.2%7.7 $11.45 9/30/20213,610,000 shares $41.12 million -5.0%11.6%8.2 $11.39 9/15/20213,800,000 shares $45.41 million -7.3%12.2%8.3 $11.95 8/31/20214,100,000 shares $51.58 million -12.6%13.2%8.7 $12.58 8/13/20214,690,000 shares $57.41 million -3.9%15.0%9.1 $12.24 7/30/20214,880,000 shares $74.81 million +2.1%15.7%9.9 $15.33 7/15/20214,780,000 shares $64.63 million +2.1%15.4%12.2 $13.52 6/30/20214,680,000 shares $65.19 million +12.0%15.1%11.4 $13.93 6/15/20214,180,000 shares $61.07 million -5.0%13.5%9.4 $14.61 5/28/20214,400,000 shares $59.97 million -5.2%14.2%8.1 $13.63 5/14/20214,640,000 shares $64.17 million +0.7%N/A8.8 $13.83 4/30/20214,610,000 shares $77.82 million +9.0%N/A8.5 $16.88 4/15/20214,230,000 shares $68.70 million +11.9%N/A7.7 $16.24 3/31/20213,780,000 shares $68.38 million +3.6%N/A7.2 $18.09 3/15/20213,650,000 shares $84.75 million -5.7%N/A7.3 $23.22 2/26/20213,870,000 shares $80.57 million +2.1%N/A10.8 $20.82 2/12/20213,790,000 shares $79.21 million +1.3%N/A10.8 $20.90 1/29/20213,740,000 shares $71.21 million -3.9%N/A10.7 $19.04 1/15/20213,890,000 shares $76.13 million -3.5%N/A10.7 $19.57 12/31/20204,030,000 shares $70.77 million +81.5%N/A11.2 $17.56 12/15/20202,220,000 shares $43.23 million -0.9%N/A5.2 $19.48 11/30/20202,240,000 shares $40.90 million -0.9%N/A5.4 $18.26 11/15/20202,260,000 shares $35.37 million -16.0%N/A5.4 $15.65 10/30/20202,690,000 shares $43.04 million +4.3%N/A6.7 $16.00 10/15/20202,580,000 shares $50.08 million -21.8%N/A6.6 $19.41 9/30/20203,300,000 shares $50.56 million +15.8%N/A7.8 $15.32 9/15/20202,850,000 shares $49.42 million -1.0%N/A7.4 $17.34 8/31/20202,880,000 shares $50.89 million +14.3%N/A8 $17.67DON’T buy gold until you read this (Ad)If you're an American who understands that your money is rotting away as you read this email… Then this is for YOU. 99% of people are buying gold the wrong way.Reserve your seat here. 8/14/20202,520,000 shares $44.60 million -3.8%N/A7.3 $17.70 7/31/20202,620,000 shares $51.14 million -3.7%N/A7.7 $19.52 7/15/20202,720,000 shares $59.81 million -2.5%N/A8.1 $21.99 6/30/20202,790,000 shares $72.54 million +10.7%N/A9.3 $26.00 6/15/20202,520,000 shares $54.23 million +0.8%N/A8.5 $21.52 5/29/20202,500,000 shares $52.18 million +2.0%N/A8.1 $20.87 5/15/20202,450,000 shares $51.45 million -6.1%N/A8 $21.00 4/30/20202,610,000 shares $52.07 million +15.5%13.9%9.2 $19.95 4/15/20202,260,000 shares $39.80 million +19.6%12.7%8.3 $17.61 3/31/20201,890,000 shares $37.54 million +39.8%10.6%7.1 $19.86 3/13/20201,351,500 shares $22.96 million +9.0%9.0%5 $16.99 2/28/20201,240,000 shares $15.25 million -4.6%8.3%4.9 $12.30 2/14/20201,300,000 shares $23.35 million +1.6%7.9%5.2 $17.96 1/31/20201,280,000 shares $23.33 million +0.8%8.1%4.9 $18.23 1/15/20201,270,000 shares $22.00 million -1.6%8.0%4.7 $17.32 12/31/20191,290,000 shares $18.86 million -7.9%8.1%4.7 $14.62 8/15/20191,014,300 shares $9.42 million +1.6%6.8%10.6 $9.29 KNSA Short Interest - Frequently Asked Questions What is Kiniksa Pharmaceuticals' current short interest? Short interest is the volume of Kiniksa Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 3,990,000 shares of KNSA short. Learn More on Kiniksa Pharmaceuticals' current short interest. What is a good short interest ratio for Kiniksa Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KNSA shares currently have a short interest ratio of 10.0. Learn More on Kiniksa Pharmaceuticals's short interest ratio. Is Kiniksa Pharmaceuticals' short interest increasing or decreasing? Kiniksa Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 3,990,000 shares, an increase of 2.0% from the previous total of 3,910,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Kiniksa Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Kiniksa Pharmaceuticals: Akero Therapeutics, Inc. (12.05%), Supernus Pharmaceuticals, Inc. (9.33%), Innoviva, Inc. (18.86%), Arcutis Biotherapeutics, Inc. (19.15%), Ocular Therapeutix, Inc. (13.70%), Pliant Therapeutics, Inc. (11.52%), Theravance Biopharma, Inc. (13.37%), Madrigal Pharmaceuticals, Inc. (19.57%), Summit Therapeutics Inc. (27.20%), BridgeBio Pharma, Inc. (11.26%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Kiniksa Pharmaceuticals stock? Short selling KNSA is an investing strategy that aims to generate trading profit from Kiniksa Pharmaceuticals as its price is falling. KNSA shares are trading down $0.46 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Kiniksa Pharmaceuticals? A short squeeze for Kiniksa Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KNSA, which in turn drives the price of the stock up even further. How often is Kiniksa Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KNSA, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: AKRO Short Interest Data SUPN Short Interest Data INVA Short Interest Data ARQT Short Interest Data OCUL Short Interest Data PLRX Short Interest Data TBPH Short Interest Data MDGL Short Interest Data SMMT Short Interest Data BBIO Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KNSA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.